PMED — Predictmedix AI Income Statement
0.000.00%
Last trade - 00:00
- CA$4.51m
- CA$4.46m
- CA$0.04m
2019 January 31st | 2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | |
---|---|---|---|---|---|
Period Length: | 14 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0.135 | 0.035 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 0.085 | 0.027 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.366 | 2.31 | 1.93 | 2.02 | 2.1 |
Operating Profit | -0.366 | -2.31 | -1.93 | -1.88 | -2.07 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -0.364 | -2.31 | -1.93 | -1.88 | -2.07 |
Net Income After Taxes | -0.364 | -2.31 | -1.93 | -1.88 | -2.07 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -0.32 | -2.29 | -1.58 | -1.88 | -2.07 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.32 | -2.29 | -1.58 | -1.88 | -2.07 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.006 | -0.008 | -0.019 | -0.017 | -0.018 |
Dividends per Share |